Semaglutide suitable for people with HIV and fatty liver disease

A study of persons with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease, also known as ‘fatty liver disease,’ (MASLD) found that semaglutide was highly effective at reducing liver fat and cardiovascular disease risk in this population. 

Read More